LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Canertinib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 2468 | 4513 | 0.5469 | 0.3760 |
MDA-MB-231 | Celastrol | 3.33 | uM | LJP6 | 72 | hr | 1235 | 780 | 4513 | 0.1728 | -0.1391 |
MDA-MB-231 | CGP60474 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 448 | 4513 | 0.0994 | -0.2402 |
MDA-MB-231 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 292 | 4513 | 0.0647 | -0.2880 |
MDA-MB-231 | CHIR-99021 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 3725 | 4513 | 0.8254 | 0.7596 |
MDA-MB-231 | CP724714 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4353 | 4513 | 0.9644 | 0.9510 |
MDA-MB-231 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 3791 | 4513 | 0.8400 | 0.7796 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1421 | 4513 | 0.3148 | 0.0565 |
MDA-MB-231 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1339 | 4513 | 0.2967 | 0.0315 |
MDA-MB-231 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 671 | 4513 | 0.1488 | -0.1722 |
MDA-MB-231 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 627 | 4513 | 0.1391 | -0.1856 |
MDA-MB-231 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1938 | 4513 | 0.4295 | 0.2144 |
MDA-MB-231 | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4809 | 4513 | 1.0654 | 1.0901 |
MDA-MB-231 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4459 | 4513 | 0.9880 | 0.9835 |
MDA-MB-231 | Foretinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1122 | 4513 | 0.2487 | -0.0347 |
MDA-MB-231 | R406 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 3183 | 4513 | 0.7053 | 0.5941 |
MDA-MB-231 | Pictilisib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 2904 | 4513 | 0.6435 | 0.5091 |
MDA-MB-231 | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4163 | 4513 | 0.9224 | 0.8931 |
MDA-MB-231 | Geldanamycin | 3.33 | uM | LJP5 | 72 | hr | 1235 | 743 | 4513 | 0.1647 | -0.1503 |
MDA-MB-231 | Geldanamycin | 3.33 | uM | LJP6 | 72 | hr | 1235 | 596 | 4513 | 0.1321 | -0.1951 |
MDA-MB-231 | GSK1059615 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1118 | 4513 | 0.2477 | -0.0360 |
MDA-MB-231 | GSK1059615 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 1188 | 4513 | 0.2632 | -0.0146 |
MDA-MB-231 | GSK1904529A | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4370 | 4513 | 0.9683 | 0.9564 |
MDA-MB-231 | Omipalisib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 824 | 4513 | 0.1826 | -0.1256 |
MDA-MB-231 | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4823 | 4513 | 1.0686 | 1.0945 |